ArticleJournal of medical radiation sciences2026
StrataXRT Versus Mepitel Film for Prevention of Acute Radiation Dermatitis in Postmastectomy Radiotherapy: A Pooled Analysis of Intra-Patient Randomised Trials.
Article in Journal of medical radiation sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe report a pooled analysis of two multicentre intra-patient randomised controlled trials (RCTs) comparing the silicone-based dressings Mepitel Film and StrataXRT for the prevention of acute radiation dermatitis (ARD) in postmastectomy radiotherapy (RT).
methodsEach irradiated chest wall was divided into medial and lateral halves, randomised to one dressing each. The primary endpoint was the incidence of grade 2 or 3 ARD. Secondary endpoints included grade 3 ARD, moist desquamation, time to moist desquamation, Radiation-Induced Skin Reaction Assessment Scale (RISRAS) scores, adverse events, and treatment preferences. Discordant-pair methods, conditional logistic regression, paired comparisons of area under the curve (AUC), and longitudinal fixed-effects regression were used.
resultsA total of 120 patients (median age, 60 years; interquartile range, 51-69) were included (Australia, n = 40; New Zealand, n = 80); 64.2% received moderately hypofractionated or ultrahypofractionated RT. Among 38 discordant pairs, grade 2 or 3 ARD occurred only on the StrataXRT side in 30 patients and only on the Mepitel Film side in eight patients (odds ratio 3.75, 95% CI 1.72-8.18; p = 0.001). Grade 3 ARD and moist desquamation did not differ significantly. HCP-assessed RISRAS AUCs for erythema (p < 0.001) and moist desquamation (p = 0.034) were significantly lower with Mepitel Film, consistent with the longitudinal analyses. Patient-reported RISRAS AUCs did not differ between treatments. Treatment preferences were broadly balanced.
conclusionsMepitel Film reduced the incidence of grade 2 or 3 ARD and cumulative HCP-assessed erythema and moist desquamation burden compared with StrataXRT, while patient-reported symptom burden was similar. Selection of a prophylactic dressing for postmastectomy RT should consider patient preference, cost, ease of application, skin sensitivity, and available resources.
trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12621000124831 and ACTRN12619001477112.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.